Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Tuberculosis treatment by restoring sensitivity to key drugs with Mycobacterial Tolerance Inhibitor
| Reference number | 2016-03721 |
| Coordinator | QURETECH BIO AB - QURETECH BIO AB c/o Akiri AB |
| Funding from Vinnova | SEK 4 000 |
| Project duration | September 2016 - September 2016 |
| Status | Completed |
Last updated 25 November 2019
Reference number 2016-03721
